Ensign Peak Advisors
EWTX icon

Ensign Peak Advisors’s Edgewise Therapeutics EWTX Stock Holding History

Ensign Peak Advisors’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.64M Buy
+40,379
New +$1.39M ﹤0.01% 779
2025
Q1 		– Sell
-80,509
Closed -$2.15M – 1698
2024
Q4 		$2.15M Buy
+80,509
New +$2.56M ﹤0.01% 904
2022
Q2 		– Sell
-662,526
Closed -$6.43M – 2178
2022
Q1 		$6.43M Buy
+662,526
New +$8.53M 0.01% 522

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ensign Peak Advisors's EWTX Position: Q2 2026 in Review

Ensign Peak Advisors opened a new position in Edgewise Therapeutics (EWTX) in Q2 2026: 40,379 shares worth $1.64M. The stake represents ﹤0.01% of the portfolio and ranks #779 among its holdings. This is a return to the name: Ensign Peak Advisors previously reported a position in EWTX as recently as Q4 2024.

Ensign Peak Advisors first reported a position in EWTX in Q1 2022 and has held it in 3 quarters since. The position peaked at $6.43M in Q1 2022. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Ensign Peak Advisors held 40,379 shares of Edgewise Therapeutics worth $1.64M as of Q2 2026.
  • Edgewise Therapeutics was a new Ensign Peak Advisors position in Q2 2026.
  • Edgewise Therapeutics made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #779 holding.
  • Ensign Peak Advisors first reported a position in Edgewise Therapeutics in Q1 2022 and has held it in 3 quarters since.
  • Ensign Peak Advisors's Edgewise Therapeutics position peaked at $6.43M in Q1 2022.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.